BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. This pan-viral protease inhibitor was discovered using the Company’s proprietary structure-based drug discovery platform technology.

2023年9月28日（GLOBE NEWSWIRE）-Cocrystal Pharma，Inc。（纳斯达克股票代码：COCP）（“Cocrystal”或“公司”），宣布第一阶段第一批受试者的剂量口服，一流的泛诺罗病毒和泛冠状病毒3CL蛋白酶抑制剂CDI-988的临床试验。这种泛病毒蛋白酶抑制剂是使用该公司专有的基于结构的药物发现平台技术发现的。

The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of oral CDI-988 in single ascending doses (SAD) including food effect cohort, and multiple ascending doses (MAD) compared to placebo in healthy volunteers. “CDI-988 is a breakthrough discovery of the first-in-class pan-coronavirus and pan-norovirus antiviral agent with potential efficacy in these two indications and we excited to take the first step in its clinical development.

第一阶段研究将评估口服CDI-988在健康志愿者中与安慰剂相比在单次递增剂量（SAD）（包括食物效应队列）和多次递增剂量（MAD）中的安全性，耐受性和药代动力学。“CDI-988是一流的泛冠状病毒和泛诺罗病毒抗病毒药物的突破性发现，在这两种适应症中具有潜在疗效，我们很高兴在临床开发中迈出第一步。

Our oral antiviral candidate has the potential to save patient lives and reduce the severity of norovirus and coronavirus infections now and in future pandemic outbreaks,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO. “We are looking forward to advancing CDI-988 to the next stage of norovirus and coronavirus clinical development upon completion of this Phase 1 study, setting up a transformational year ahead for Cocrystal.” Recent CDI-988 in vitro studies showed potent broad-spectrum antiviral activity against a panel of pandemic GII.4 norovirus proteases and a favorable pharmacokinetic property targeting the gastrointestinal tract.

Cocrystal的总裁兼联合首席执行官Sam Lee博士说，我们的口服抗病毒候选药物有可能挽救患者的生命，并降低诺如病毒和冠状病毒感染的严重程度。“我们期待在完成第一阶段研究后，将CDI-988推进诺如病毒和冠状病毒临床开发的下一阶段，为共晶建立一个转型年。“最近的CDI-988体外研究显示针对一组大流行性GII.4诺如病毒蛋白酶的有效广谱抗病毒活性和针对胃肠道的有利的药代动力学性质。

GII.4 proteases have caused the majority of norovirus outbreaks worldwide since 2002 and represent an unmet medical need for an approved antiviral treatment and vaccine against noroviruses. “We believe CDI-988 to be a gamechanger in providing an effective targeted, oral tr.

GII.4蛋白酶自2002年以来已引起全球大部分诺如病毒爆发，并且代表了对批准的抗病毒治疗和针对诺如病毒的疫苗的未满足的医疗需求。“我们相信CDI-988在提供有效的靶向口服tr方面是一种改变游戏规则。